Introduction {#Sec1}
============

Statins are a highly effective treatment for dyslipidemias \[[@CR1]\]. They have been shown to reduce the risk of ischemic heart disease and stroke, and are one of the most commonly prescribed medications. In 2011, 13.0% of Britain's population and Slovakia's population were prescribed a statin or statin-like drug, followed by Belgium (12.2%), Norway (11.6%), and Denmark (11.5%), and with similar patterns throughout Europe \[[@CR2]\]. In light of their prevalence, it is important to understand potential adverse drug reactions (ADRs) reported by patients that are associated with the use of statins.

While a number of studies have explored statin-associated adverse effects, there remains a lack of standard definitions of statin intolerance \[[@CR3]\] or a clear clinical presentation of statin-related symptoms (e.g., myalgia) \[[@CR4]\]. No biomarkers are currently available to detect the most common symptoms, statin-associated muscle symptoms \[[@CR5]\] or additional symptoms that patients report. Differences in study design and nonuniformity of assessment tools have contributed to conflicting conclusions about the prevalence and severity of statin-associated ADRs \[[@CR6]\]. This is further complicated by differing rates of reported adverse effects in clinical practice versus clinical trials, with clinical trials showing very low rates of ADRs \[[@CR7]\]. Symptoms that have been reported to be associated with statin use are primarily muscle symptoms, but also include gastrointestinal, renal, and hepatic issues, mood and psychological disorders, and problems with cognition and memory \[[@CR8], [@CR9]\]. The symptoms and severity of statin intolerance vary from patient to patient and from medication to medication \[[@CR10]\]. Notably, most patients who experience statin intolerance to one medication can tolerate subsequent trials of other statins \[[@CR9]\].

We aimed to identify and understand the characteristics of statin intolerance from the perspective of the patient who is taking statins and experiencing difficulties. The overall objective of this work is to produce a patient survey to describe the burden of patient-perceived statin intolerance and potentially identify prospective patients who may have the same types of difficulties with statin treatment. This manuscript describes the qualitative study conducted to support the development of the content included in the patient survey.

Methods {#Sec2}
=======

Literature Review {#Sec3}
-----------------

The first step in the development of the survey was to conduct a review of the literature to identify key elements of the patient experience that could be relevant in assessing symptom severity and life impacts in patients experiencing statin intolerance. We conducted a systematic search of articles published during 2001--2016 in PubMed. Additional articles were provided by the European Atherosclerosis Society. A total of 35 full articles that reported concepts of statin-related symptoms or impact were reviewed. Symptoms reported in the literature reviewed included muscle-related, gastrointestinal, renal/hepatic, mood/psychological, and cognition symptoms and pain (Supplemental Table S1). Impacts identified from the literature review included limitations on physical functioning and daily activities, fatigue, sleep, and the patient--clinician relationship.

Clinician Interviews {#Sec4}
--------------------

A steering committee was formed to identify a sample of cardiovascular clinicians working in dyslipidemia across seven European countries: the Czech Republic, Italy, Norway, Slovakia, Spain, Sweden, and the UK. Sites were selected to represent different cultures and different types of practice settings. All clinicians had a current practice treating hyperlipidemia, experience using statins, and a concern about patients who experience difficulties with their statin treatment. Clinicians participated in two 60-min telephone interviews using a semi-structured interview guide. Interviews were transcribed and used to summarize responses against key questions and topics.

Results from the literature review and clinician interviews were used to inform the content of the interview guide for patient concept elicitation interviews with patients.

Patient Interviews {#Sec5}
------------------

Qualitative interviews were conducted with patients having difficulty with their prescribed statin treatment. These interviews were used to identify concepts relevant to the patient experience, and of interest to have included in the patient survey. Participants were identified and recruited by clinicians from 12 different study sites in the EU. These were two sites each in the Czech Republic, Italy, Spain, Slovakia, and Sweden and one site each in the UK and Norway. Ethics committee approval was obtained for each study site (Supplemental List S1), and all participants provided written informed consent prior to initiation of any study activity.

Eligible participants were ≥ 18 years of age at screening, had been treated with ≥ 1 statin within the 3 years prior to screening, and their prescribing physician had taken at least one of the following actions to address a side effect or symptom attributable (by either the patient or physician) to the prescribed statin therapy:Statin therapy had been discontinued completely;A switch to another statin occurred or prescribed dosage was lowered; and/orAdditional therapy (including nonprescribed medications, herbal medications, vitamins) was initiated.

Patients were excluded from the study if the action to change statin therapy was not based on a statin-related symptom (e.g., symptom related to a different medication or other pre-existing condition), had a pre-existing neuromuscular condition (e.g., fibromyalgia, multiple sclerosis, muscular dystrophy), or untreated hypothyroidism.

Patients completed a demographic questionnaire during their enrollment visit and were scheduled for an individual face-to-face interview session. All interviews were conducted in person, in the native language of each country, and were audio-recorded and transcribed. During each interview, the semi-structured interview guide was used to elicit descriptions of the patient experience with statin-related difficulties. Interviews were all conducted in commercial research facilities and monitored by senior project staff. Simultaneous translation was used to provide the monitor with details of the interview in real time and to generate an English voice file for transcription. The transcripts were coded using Atlas-ti software by multiple coders to identify predominant statin-related symptoms and impact concepts.

To evaluate the consistency between coders and reliability of the coding process, a formal assessment of inter-rater agreement was conducted. Approximately 10% of concept elicitation transcripts were independently dual-coded; the resulting transcript pairs were compared to evaluate any differences in the code assignment between the two coders. Upon completion of the coding process, saturation of concept (the point at which no new information is forthcoming from the concept elicitation interviews) was evaluated. Transcripts were ordered chronologically by the date conducted and divided into six groups. Each group of interviews was evaluated to identify the appearance of new information (new codes) and compared to the previous group to identify the point at which the interviews were no longer providing new information. This would indicate that no further information would be expected by continuing interviews with this population.

During the interview process, patients were asked to rate the severity of their symptoms on a scale of 0 (none) to 10 (extremely severe), and the bothersomeness of their symptoms on a scale of 0 (not bothersome at all) to 10 (extremely bothersome). Patients were also asked to rate the difficulty of the impacts of statin intolerance on their lives using a scale of 0 (not at all difficult to cope with) to 10 (extremely difficult to cope with).

Survey Development {#Sec6}
------------------

The concept elicitation interview results were presented to the Steering Committee for discussion and decisions regarding the content that should be covered by the patient survey. Following these discussions, a conceptual framework was developed to reflect the proposed structure and subdomains, and a preliminary draft of the patient questionnaire was developed in English. Once the measure was approved by the team, the contents were translated into the appropriate language for each participating country. Country-specific information (such as the statin list that might be prescribed in each country) was reviewed by the site investigators, and the patient survey was prepared for the next step of assessment, in which the clarity and understandability of the items are checked with patients using cognitive interviews prior to the use of the survey for data collection.

Results {#Sec7}
=======

Clinician Interviews {#Sec8}
--------------------

Fourteen clinicians participated in interviews, representing two hospital practices, five outpatient clinics, six specialty lipid clinics, and one private practice. Eight clinicians had \> 20 years of clinical experience. The frequency reported for patient visits for dyslipidemia ranged between 2 and 3 months up to 6 months or annually. The clinicians' perceptions of specific symptoms and impacts of statin intolerance are shown in Supplemental Table S2, and clinician quotations defining statin intolerance are reported in Supplemental Table S3. Most complaints received by clinicians were described by them as being about general activity limitation and reduced quality of life, tied largely to the types of activities that the patients felt were restricted (including choice of sports, everyday work, and walking for health and exercise). Two clinicians reported patient complaints that affected their sleep, and therefore had other quality of life repercussions on their subsequent days, such as chronic tiredness and fatigue.

When asked about determining whether or not a symptom was statin-related, 11 clinicians (79%) indicated that they would base their decision on the typical practice of statin challenge, whereby the statin is discontinued and the patient is watched to see if the symptoms disappear, and 10 clinicians (71%) indicated they would base their decisions on the results of medical tests (e.g., liver function, thyroid function, creatine kinase levels).

Patients {#Sec9}
--------

A total of 65 patients participated in concept elicitation interviews from the Czech Republic (*n* = 10), Italy (*n* = 10), Norway (*n* = 8), Slovakia (*n* = 10), Spain (*n* = 10), Sweden (*n* = 9), and the UK (*n* = 8). The mean age was 61.5 years \[standard deviation (SD) 11.5\] and slightly over half of the participants were male (54%) (Table [1](#Tab1){ref-type="table"}). More than half of the patients (60%) were no longer using a statin and several of these patients remarked during the interview process that they discontinued their statin treatment without consulting or informing their clinician.Table 1Demographic and clinical characteristics of participating patientsCzech Republic (*n* = 10)Italy (*n* = 10)Norway (*n* = 8)Slovakia (*n* = 10)Spain (*n* = 10)Sweden (*n* = 9)United Kingdom (*n* = 8)All patients (*n* = 65)Age, mean years (SD)62.2 (7.4)60.8 (7.1)59.5 (8.9)59.9 (14.9)63.5 (11.6)63.1 (17.9)NA61.5 (11.5)Sex, *n* male (%)5 (50)7 (70)4 (50)4 (40)7 (70)6 (67)2 (25)35 (54)Highest education level, *n* (%) High school only00001 (10)001 (2) Some college6 (60)5 (50)2 (25)6 (60)5 (50)7 (78)031 (48) Bachelor's degree1 (10)3 (30)1 (13)4 (40)3 (30)2 (22)3 (38)17 (26) Graduate/professional school3 (30)2 (20)5 (63)01 (10)05 (63)16 (25)Employment status, *n* (%) Employed full-time4 (40)5 (50)3 (38)3 (30)4 (40)2 (22)021 (32) Employed part-time1 (10)00001 (11)02 (3) Self-employed1 (10)2 (20)01 (10)1 (10)03 (38)8 (12) Retired4 (40)3 (30)4 (50)6 (60)4 (40)6 (67)5 (63)32 (49) Unable to work001 (13)01 (10)002 (3)Select comorbid conditions, *n* (%) Cardiovascular disease5 (50)6 (60)3 (38)4 (40)6 (60)6 (67)4 (50)34 (52) Hypertension4 (40)3 (30)2 (25)6 (60)5 (50)9 (100)3 (38)32 (49) FH4 (40)8 (80)4 (50)4 (40)2 (20)01 (13)23 (35) Diabetes001 (13)4 (40)02 (22)07 (11) Depression00000000 Sleep apnea003 (38)00003 (5)Time since first statin prescription, mean years (SD)9.9 (9.4)8.5 (6.7)14.9 (13.9)6.9 (6.8)9.9 (11.8)12.2 (8.0)10.1 (8.4)10.3 (9.4)Satisfaction with current treatment,^a^ mean score (SD) \[*n*\]5.2 (4.9) \[8\]3.9 (3.9) \[7\]5.3 (4.5) \[6\]4.9 (3.9) \[10\]6.2 (4.4) \[7\]10.0 (0.0) \[3\]4.0 (NC) \[1\]5.4 (4.1) \[42\]Current number of statins, *n* (%) 08 (80)5 (50)3 (38)7 (70)2 (20)8 (89)6 (75)39 (60) 12 (20)3 (30)2 (25)3 (30)6 (60)1 (11)2 (25)19 (29) 202 (20)3 (38)02 (20)007 (11)*FH* familial hypercholesterolemia, *\[n\]* patients with data available, *NA* not available, *NC* not calculated, *SD* standard deviation^a^Satisfaction with treatment was scored on a numerical rating scale from 0 (not satisfied at all) to 10 (extremely satisfied)

Results of Concept Elicitation Interviews {#Sec10}
-----------------------------------------

A total of 5485 different quotations were coded as concepts from the 65 transcripts, and grouped by similarity of content. Symptoms expressed by patients included muscle-related pain and discomfort, non-muscle-related pain and discomfort, muscle-related symptoms that were different than pain, gastrointestinal symptoms, cardiovascular symptoms, cold-like symptoms, mood changes due to medication, cognitive and memory problems, fatigue-related symptoms, and sensory and systems symptoms (Table [2](#Tab2){ref-type="table"}). Impacts expressed by patients included limitations on physical functioning in general, physical activities, and social functioning. Patients also noted emotional impacts, sleep disturbances, impacts on productivity, and increased use of healthcare (Table [3](#Tab3){ref-type="table"}).Table 2Statin intolerance symptom code frequenciesSymptomsNo. patient language expressions within concept% of 2069 symptom expressions (%)No. transcripts contributing to concept expression% of 65 transcripts contributing (%)Non-muscle-related pain and discomfort28914 Arthritis and bone symptoms1818.73350.8 Bone and joint weakness50.234.6 Burning and stinging211.069.2 Headache231.1710.8 Non-muscle neck and back pain150.7710.8 Non-muscle pain or discomfort442.11116.9Muscle-related pain or discomfort57428 Muscle ache1065.13350.8 Muscle burning70.311.5 Cramps1527.33249.2 Muscle pulls and tears60.346.2 Soreness and tenderness472.32335.4 Muscle pain or discomfort25612.45076.9Non-pain muscle-related symptoms27913 Muscle weakness1165.63249.2 Muscle stiffness and tightness904.33350.8 Muscle tingling271.3812.3 Muscle loss211.057.7 Muscle lump40.211.5 Other muscle issues^a^211.0812.3Gastrointestinal symptoms1156 Abdominal discomfort80.434.6 Abdominal pain or cramps291.41116.9 Acid reflux40.223.1 Bloating40.223.1 Constipation80.446.2 Diarrhea321.51116.9 Nausea231.1812.3 Stool changes40.211.5 Vomiting30.111.5Cardiovascular symptoms281 Arrhythmia40.211.5 Blood pressure changes60.334.6 Chest pain40.223.1 Difficulty breathing90.457.7 Heart palpitations30.111.5 Increased heart rate20.111.5Cold-like symptoms1276 Chills70.369.2 Coughing30.123.1 Dizziness321.51218.5 Feels hot120.634.6 Feels sick or poorly442.11827.7 Runny or stuffy nose70.369.2 Sneezing20.123.1 Throat symptoms190.9913.8 Other cold-like symptoms^b^1\< 0.111.5Mood changes due to medication945 Anxiety281.41015.4 Apathy40.211.5 Depression452.21624.6 Hostility or agitation110.557.7 Lack of confidence50.211.5 Other mood changes^c^1\< 0.111.5Cognitive and memory problems1085 Cognitive problems442.11421.5 Memory problems643.11624.6Fatigue-related symptoms29914 Exhaustion452.22132.3 Fatigue502.42233.8 Lack of energy763.73147.7 Tiredness1185.73655.4 Weakness100.569.2Sensory and systems problems673 Eye symptoms40.223.1 Ear symptoms50.234.6 Mouth symptoms30.111.5 Skin and hair symptoms552.71218.5Additional symptoms894 Allergy1\< 0.111.5 High blood sugar1\< 0.111.5 Infections1\< 0.111.5 Kidney problems100.5710.8 Liver problems201.0710.8 Sweating80.457.7 Swelling or inflammation261.31116.9 Uncoordinated movement40.211.5 Weight-related symptoms180.957.7^a^Other muscle issues included congestion, creatine kinase, heat, and spine blocked^b^Other cold-like symptoms included heavy head^c^Other mood changes included suicidal thoughtsTable 3Statin intolerance impact code frequenciesConcept descriptionNo. patient language expressions within concept% of 1275 impact expressionsNo. transcripts contributing to concept expression% of 65 transcripts contributingImpacts on physical activities and functioning46136 Falls60.523.1 Hand function limited90.769.2 Have to rest more574.53046.2 Physical activities limited18314.45076.9 Physical functioning limited20616.24873.8Impacts on social functioning17013 Activity harder50.446.2 Altered close relationships201.61116.9 Altered relationships with friends80.6710.8 General functioning limited604.73553.8 Lifestyle restrictions312.41929.2 Sexual activity40.323.1 Social activities affected423.32640.0Emotional Impacts28322 Anxiety806.32843.1 Apathy50.423.1 Depression514.02233.8 Frustration272.11421.5 Hopelessness50.434.6 Hostility or aggression383.01929.2 Lack of confidence120.91015.4 Mental Tiredness50.423.1 Stress161.31015.4 Worry443.52030.8Sleep disturbances12410 Difficulty falling asleep302.42233.8 Difficulty staying asleep493.82538.5 Poor quality sleep453.52335.4Impacts on productivity13210 Diminished work252.01523.1 Limitations to chores342.71726.2 Poor performance or productivity433.42030.8 Trouble reading50.434.6 Work more difficult252.01726.2Use of healthcare585 Increased doctor visits423.33350.8 Increased hospitalization120.9913.8 Treatment burden40.346.2Additional impacts474 Altered attire90.734.6 Dietary changes30.223.1 Financial burden20.223.1 Increased dependence20.223.1 Overall quality of life312.42233.8

While a few new codes were still coming forward in the last transcript group for the saturation analysis, it was clear from the content that the concepts being expressed were not new concepts but the use of different language to describe the same concept, and were basically reflecting the variation between language use in the countries. Therefore, the developers felt confident that all relevant concepts from this group of patients were registered for consideration. Inter-rater agreement ranged between 94.0 to 98.5% for the assignment of codes.

Patients were asked to rate the severity and bothersomeness of statin-related symptoms (Table [4](#Tab4){ref-type="table"}). Notably, some symptoms with higher severity ratings were associated with low levels of bothersomeness (e.g., cold-like symptoms of chills), and conversely, some symptoms with lower severity ratings had higher bothersomeness ratings (e.g., constipation). Patients were also asked to rate the difficulty of statin-related impacts (Table [5](#Tab5){ref-type="table"}). Based on these ratings, impacts on relationships had the highest (i.e., greatest difficulty) ratings. The severity and bothersomeness ratings were used in conjunction with the coded transcript data to determine the most relevant content to include in the design of the survey.Table 4Statin intolerance symptom severity and bothersomeness ratingsSymptomsAll patients (*n* = 65)Symptom severitySymptom bothersomeness*n*Mean score (SD) \[range\]*n*Mean score (SD) \[range\]Non-muscle-related pain and discomfort Arthritis and bone symptoms  Bone or joint ache107.7 (0.9) \[6--9\]47.8 (2.1) \[6--10\]  Bone or joint pain35.7 (2.9) \[4--9\]267.7 (2.1) \[3--10\]  Stiff or cracking joints36.7 (3.5) \[3--10\]210.0 (0) \[10\]  Soreness57.8 (2.0) \[6--10\]77.1 (3.0) \[3--10\]  Tenderness37.0 (1.7) \[5--8\]77.7 (1.3) \[6--10\] Bone or joint weakness  Joint weakness0NA18.0 Burning and stinging  Burning28.5 (2.1) \[7--10\]19.0  Stinging0NA18.0 Headache47.3 (2.1) \[5--10\]56.2 (2.2) \[5--10\] Non-muscle neck or back pain0NA68.2 (3.0) \[3--10\] Non-muscle pain or discomfort217.4 (2.0) \[2--10\]147.6 (1.6) \[5--10\]Muscle-related pain or discomfort Muscle ache237.4 (2.1) \[3--10\]286.4 (2.0) \[2--10\] Muscle burning0NA17.0 Muscle cramps257.4 (2.2) \[2--10\]267.0 (2.5) \[2--10\] Muscle tears110.029.0 (1.4) \[8--10\] Soreness and tenderness  Soreness128.1 (1.8) \[5--10\]146.8 (1.9) \[4--10\]  Tenderness88.3 (1.7) \[5--10\]77.0 (1.9) \[4--10\] Muscle pain or discomfort397.2 (2.3) \[3--10\]267.1 (2.4) \[1--10\]Non-pain muscle-related symptoms Muscle weakness  Muscle fatigue137.7 (2.6) \[1--10\]137.1 (2.2) \[4--10\]  Muscle heaviness187.0 (2.5) \[1--10\]186.9 (2.2) \[2--10\]  Muscle weakness197.4 (1.9) \[5--10\]267.0 (2.0) \[2--10\] Muscle stiffness197.1 (2.5) \[3--10\]286.4 (2.2) \[1--10\] Muscle tingling15.056.2 (1.3) \[5--8\] Muscle loss  Lack of tone15.017.0  Muscle loss13.546.0 (1.8) \[4--8\]  Muscle wasting0NA110.0 Muscle lump0NA16.0 Warm/heat in upper leg; blocking spine chest part28.8 (1.8) \[7.5--10\]28.5 (2.1) \[7--10\]Gastrointestinal symptoms Abdominal discomfort  Poor digestion18.018.0 Abdominal pain or cramps68.0 (1.4) \[6--10\]86.4 (2.3) \[3--9\] Acid reflux110.0110.0 Bloating27.5 (0.7) \[7--8\]17.0 Constipation25.0 (2.8) \[3--7\]38.0 (2.0) \[6--10\] Diarrhea97.3 (1.9) \[4--9\]116.1 (2.8) \[1--10\] Nausea57.2 (2.6) \[4--10\]66.7 (3.4) \[2--10\] Stool changes0NA17.0 Vomiting46.8 (2.8) \[4--10\]27.5 (3.5) \[5--10\]Cardiovascular symptoms Difficulty breathing0NA49.3 (1.0) \[8--10\] Heart palpitations18.527.0 (2.8) \[5--9\] Increased heart rate15.00NACold-like symptoms Chills27.0 (1.4) \[6--8\]35.3 (2.1) \[3--7\] Dizziness  Dizziness28.5 (0.7) \[8--9\]29.0 (1.4) \[8--10\]  Feels faint29.5 (0.7) \[9--10\]110.0 Feels sick or poorly66.8 (1.8) \[5--10\]86.9 (2.5) \[2--10\] Feels hot27.0 (1.4) \[6--8\]27.5 (2.1) \[6--9\] Runny or stuffy nose38.7 (1.2) \[8--10\]45.3 (3.0) \[2--9\] Sneezing18.044.0 (0.8) \[3--5\] Throat symptoms  Sore throat56.5 (2.8) \[3--9.5\]85.5 (2.7) \[1--9\]Mood changes due to medication Anxiety  Anxiety127.8 (2.8) \[1--10\]128.4 (1.2) \[6--10\]  Nervous0NA18.0 Depression  Depression69.2 (1.3) \[7--10\]77.9 (1.7) \[5--10\]  Low mood15.016.0  Sadness29.5 (0.7) \[9--10\]37.7 (1.5) \[6--9\]  Mood changes0NA17.0 Hostility or agitation58.4 (2.2) \[6--10\]66.8 (2.8) \[3--10\]Cognitive and memory problems Cognitive symptoms  Fuzzy thoughts0NA19.0  Difficulty concentrating28.5 (2.1) \[7--10\]68.8 (1.2) \[7--10\] Memory problems  Amnesia210.0 (0.0) \[10\]0NA  Memory problems107.2 (2.3) \[4--10\]108.2 (2.1) \[4--10\]Fatigue-related symptoms Fatigue0NA157.1 (1.9) \[3--10\] Exhaustion177.3 (1.8) \[5--10\]227.5 (2.0) \[2--10\] Lack of energy247.1 (2.2) \[3--10\]267.4 (2.1) \[2--10\] Tiredness246.7 (2.3) \[3--10\]217.3 (2.0) \[5--10\]Sensory and systems problems Skin and hair symptoms  Bruising12.016.0  Eczema0NA16.0  Hair loss29.0 (0.0) \[9\]210.0 (0.0) \[10\]  Rash28.5 (2.1) \[7--10\]210.0 (0.0) \[10\]  Sensitive skin0NA29.5 (0.7) \[9--10\]  Skin ulcers16.0110.0Additional symptoms Kidney problems  Frequent urination0NA27.0 (4.2) \[4--10\] Liver problems18.027.0 (4.2) \[4--10\] Sweating0NA29.0 (1.4) \[8--10\] Swelling or inflammation  Swelling29.5 (0.7) \[9--10\]48.3 (1.7) \[6--10\] Weight-related symptoms  Fat loss0NA10.0  Weight gain110.0110.0*n* number of patients rating symptom, *NA* not applicable, *SD* standard deviationTable 5Statin intolerance impact difficulty ratingsConcept descriptionAll patients (*n* = 65)*n*Mean score (SD) \[range\]Impacts on physical activities and functioning Falls13.0 Have to rest more176.8 (1.6) \[4--9\] Physical activities limited326.5 (2.6) \[1--10\] Physical functioning limited267.1 (2.5) \[1--10\]Impacts on social functioning Altered close relationships58.4 (1.7) \[6--10\] Altered relationships with friends29.0 (1.4) \[8--10\] Sexual activity18.0 Social activities affected165.7 (2.3) \[1--8\] Lifestyle restrictions157.2 (1.6) \[5--10\] General functioning limited126.0 (2.0) \[3--9\] Activity harder16.0Emotional impacts Anxiety136.8 (2.6) \[3--10\] Mentally tired110.0 Stress16.0 Worry166.9 (2.1) \[2--10\] Depression  Depression87.3 (1.7) \[5--10\]  Low mood35.7 (2.5) \[3--8\]  Sadness156.0 (2.5) \[3--10\] Frustration  Annoyance16.0  Frustration117.9 (1.8) \[4--10\] Hostility or agitation  Anger46.8 (2.1) \[4--9\]  Irritability18.0 Lack of confidence  Embarrassment66.2 (3.5) \[1--10\]  Self-deprecation18.0Sleep disturbances Difficulty falling asleep106.6 (2.9) \[3--10\] Difficulty staying asleep68.0 (1.7) \[5--10\] Poor quality sleep237.3 (2.0) \[3--10\]Impacts on productivity Diminished work106.8 (3.1) \[0--10\] Limitations to chores87.4 (1.8) \[5--10\] Poor performance or productivity176.6 (3.0) \[0--10\] Work more difficult15.0Use of healthcare Increased doctor visits235.8 (2.9) \[0--10\] Increased hospitalization47.8 (2.6) \[4--10\]Additional impacts Altered attire110.0 Increased dependence18.0 Overall quality of life18.0*n* number of patients rating symptom, *NA* not applicable, *SD* standard deviation

Conceptual Framework for Statin Intolerance Patient Survey {#Sec11}
----------------------------------------------------------

The goals of the survey are to help describe statin intolerance from the patient perspective, inform clinical practice around statin intolerance, and to identify potential risk characteristics or barriers that may result in patients giving up and discontinuing their statin treatment. Six key elements were identified for the conceptual framework for the survey (Table [6](#Tab6){ref-type="table"}): (1) respondent demographics; (2) clinical characteristics; (3) health information and beliefs; (4) statin side effect history; (5) symptom severity; and (6) impact severity.Table 6Conceptual framework for statin intolerance patient surveyConceptItems for surveyRespondent demographicsAgeSexMarital statusEducation levelEmployment statusClinical characteristicsStatin intolerant group (Y/N)Self-reported health statusComorbid conditionsPerception of risk for myocardial infarctionDiagnosis of familial hypercholesterolemiaFamily history of medical conditionsHistory of non-statin side effectsKnowing others who have discontinued a statinCurrent prescriptions per dayCurrent over-the-counter medications per dayActivity levelAlcoholSmokingPatient Health Questionnaire (PHQ-4)Health information and beliefsComfort level with Dr.Quality of communication with Dr.Type of Dr. providing prescribing statinFeels listened to by Dr.Willingness to try another statinLevel of involvement with medical care decisionsSatisfaction with information from Dr.Information sources (frequency of use, level of trust)Reason for taking a statinReason for not taking a statinCholesterol under control or notStatin side effect historyStatins takenCurrent use of a statin or notSide effects with previous statinType of side effectsSide effects with current or most recent statinTime to onset of side effectsSide effect interference with activitiesType of changes made to address side effectsImprovements after changes madeTime to improvementTiming of most recent side effect experienceCurrent over-the-counter supplementSymptom severityMuscle achesMuscle crampsMuscle painMuscle sorenessMuscle stiffnessMuscle weaknessBone and joint painAbdominal painLack of energyTires easilyExhaustionFatigueMemory problemsIrritabilityFrustrationImpact severityNeeding to rest moreReduced ability to be physically activeLimited social activitiesIncreased office visitsReduced productivity or performanceReduced ability to exerciseTrouble getting good quality sleep

Discussion {#Sec12}
==========

While a number of studies have explored statin-associated adverse effects, the lack of standard definitions of statin intolerance and associated symptoms \[[@CR3]\], as well as nonuniformity of the outcomes measured, make it difficult to identify the patients having difficulty with their statin treatment and, more importantly, those at risk for discontinuing their treatment because of the difficulties \[[@CR11]\]. Our literature search revealed a notable lack of patient-centered research in the field. There are currently no validated patient-reported outcome measures to assess the symptoms or impacts of statin intolerance. With the introduction of new lipid-lowering therapies for the treatment of dyslipidemias, it is increasingly important to identify patients having difficulties with their statin treatment to ensure timely and clinically beneficial treatment modifications \[[@CR12]\]. Our goal is to develop a patient survey to describe the patient experience with statin intolerance to inform clinical practice and assist with identification of patients who may need extra attention to help keep them on a treatment regimen.

This qualitative study identified key symptoms and impacts associated with statin intolerance that were highly relevant to the patient experience. Symptoms of muscle-related pain or discomfort were the most commonly reported statin-related symptoms reported by patients, appearing in 77% of interviews and comprising 28% of symptom expressions. Impacts on physical functioning were the most commonly reported statin-related impacts reported by patients, representing 36% of impact expressions. These observations were consistent with information obtained from the literature review and from clinician interviews. However, the results also showed that the symptom and impact experience from the patient perspective is broader than currently reflected in the literature and assumed by clinicians. While not all of the concepts expressed will be reflected in the survey, those with relevance to larger numbers of the patients interviewed will be included.

Ultimately, results from the patient survey will support clinician awareness for effective decision-making. Evaluation of symptom severity and impact severity will assist with describing the patients who experience a greater symptom and impact burden and have a higher risk of giving up and discontinuing their treatment. While statin side effect histories provide a clinically descriptive picture of the patient's journey through the difficulties with statin treatment, these histories can also provide key information regarding tendencies toward continuing or discontinuing statin use. Other key elements in the conceptual framework are expected to provide insight into which patient characteristics might indicate a possible association with discontinuing statin treatment, and help clinicians identify possible ways to assist those patients in staying on treatment.

Qualitative studies have inherent limitations, including the possibility of selection bias in the recruitment of sites and patients. The inclusion criteria were selected to intentionally focus on patients who had a recent experience with statins and who returned to their doctor reporting difficulties as a result of the statin. While the patients selected across sites may not be representative of all patients having difficulties with their statins, the group interviewed were from a variety of countries and sites, and the saturation evaluation provides good evidence that sufficient representation of the key concepts from this population came forward in the interview process and was considered.

Conclusions {#Sec13}
===========

Qualitative interviews prompted patients to address a wider range of symptoms and impacts than are usually discussed in clinic visits. A better understanding of the symptoms and impacts that patients experience with statin use may assist clinicians with managing individual patients in a way that provides options that encourage adherence to treatment. The next steps of this research will be to confirm the clarity and understandability of the items in the survey using cognitive interviews, and then to use the survey to obtain a quantitative dataset that can be used to address the outstanding questions of the study.
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